Sun Pharma reports a 26% rise in Q4 net profit, driven by strong sales and ongoing investments in innovative products.

Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages…

Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore…

Sun Pharma's Q4 net profit rises 26% to ₹2,714 crore, driven by robust formulation sales and strong overall revenue growth.

Sun Pharma reports a 26% rise in Q4 net profit, driven by strong sales and ongoing investments in innovative products.

Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on…

Sun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and lower milestone income. The company…